Theravance Biopharma to Engage in Investor Conferences This December

Theravance Biopharma, Inc. (NASDAQ: TBPH), is set to make its presence felt at several prominent investor conferences this December. The company announced today that its management will actively participate in key discussions, events that offer a platform for engaging with investors and sharing insights about their ongoing endeavors.

Conference Details

1. 8th Annual Evercore Healthcare Conference
- Location: Coral Gables, FL
- Format: Fireside Chat
- Date: Thursday, December 4, 2025
- Time: 8:20 - 8:40 AM ET

2. Oppenheimer Movers in Rare Disease Summit
- Location: New York, NY
- Format: Panel Discussion featuring brief elevator pitches from rare disease companies showcasing potential stock-moving catalysts.
- Date: Thursday, December 11, 2025
- Time: 2:15 - 2:45 PM ET

During both events, Theravance Biopharma will be available for one-on-one meetings, allowing interested investors to connect directly with the company’s representatives. This is an excellent opportunity for investors to gain deeper insights into the company’s strategy and future prospects.

Live Webcast Availability

For those who cannot attend in person, Theravance will provide a live webcast of the Evercore presentation. Investors and interested parties can access the stream through the "Events and Presentation" page on Theravance’s official website. Additionally, a recorded version of the webcast will be available for 30 days post-event, ensuring that key highlights and discussions are accessible to a broader audience.

About Theravance Biopharma

Theravance Biopharma's mission is to create meaningful medical solutions through innovation, striving to deliver "Medicines that Make a Difference®" in patients' lives. Among its notable achievements is the development of YUPELRI® (revefenacin), an FDA-approved inhalation solution designed for maintaining treatment in patients with chronic obstructive pulmonary disease (COPD).

Furthermore, the company is advancing its investigational therapies, including Ampreloxetine, which is in late-stage development as a once-daily norepinephrine reuptake inhibitor intended for treating neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). This innovative therapy has the potential to revolutionize treatment for MSA patients, addressing a combination of significant symptoms that greatly affect their quality of life.

Theravance Biopharma remains committed to generating shareholder value through rigorous development programs and innovative treatments.

For more on the company's developments and updates, please visit www.theravance.com.

Contact Information

For media inquiries, please reach out at:
Email: [email protected]
Phone: 650-808-4045

Disclaimer: All trademarks mentioned including THERAVANCE BIOPHARMA®, THERAVANCE®, and YUPELRI® are the property of their respective owners.